Free Trial

AstraZeneca (AZN) Stock Forecast & Price Target

AstraZeneca logo
$73.01 +0.13 (+0.18%)
Closing price 06/9/2025 04:00 PM Eastern
Extended Trading
$72.50 -0.51 (-0.69%)
As of 05:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AstraZeneca - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
7

Based on 8 Wall Street analysts who have issued ratings for AstraZeneca in the last 12 months, the stock has a consensus rating of "Buy." Out of the 8 analysts, 1 has given a hold rating, 5 have given a buy rating, and 2 have given a strong buy rating for AZN.

Consensus Price Target

$85.00
16.42% Upside
According to the 8 analysts' twelve-month price targets for AstraZeneca, the average price target is $85.00. The highest price target for AZN is $95.00, while the lowest price target for AZN is $75.00. The average price target represents a forecasted upside of 16.42% from the current price of $73.01.
Get the Latest News and Ratings for AZN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for AstraZeneca and its competitors.

Sign Up

AZN Analyst Ratings Over Time

TypeCurrent Forecast
6/10/24 to 6/10/25
1 Month Ago
5/11/24 to 5/11/25
3 Months Ago
3/12/24 to 3/12/25
1 Year Ago
6/11/23 to 6/10/24
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
2 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
7 Buy rating(s)
7 Buy rating(s)
6 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$85.00$88.00$89.75$88.00
Forecasted Upside16.42% Upside30.24% Upside18.76% Upside9.71% Upside
Consensus Rating
Buy
Buy
Buy
Moderate Buy

AZN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AZN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

AstraZeneca Stock vs. The Competition

TypeAstraZenecaMedical CompaniesS&P 500
Consensus Rating Score
3.13
2.81
2.53
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside16.42% Upside5,918.80% Upside13.46% Upside
News Sentiment Rating
Positive News

See Recent AZN News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/15/2025BNP Paribas
4 of 5 stars
P. Verdult
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$75.00+11.09%
2/13/2025UBS Group
3 of 5 stars
M. Weston
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy
2/12/2025Morgan Stanley
3 of 5 stars
 Initiated CoverageOverweight
11/6/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeSell ➝ Hold
9/11/2024Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
8/12/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$90.00 ➝ $95.00+16.29%
6/24/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
P. Verdult
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/24/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
E. Field
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
5/30/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$80.00 ➝ $85.00+10.72%
5/30/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$97.00+27.50%
4/26/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$80.00 ➝ $82.00+8.70%
1/3/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
12/18/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 05:10 AM ET.


Should I Buy AstraZeneca Stock? AZN Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Monday, June 9, 2025. Please send any questions or comments about these AstraZeneca pros and cons to contact@marketbeat.com.

AstraZeneca
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in AstraZeneca:

  • AstraZeneca has demonstrated strong financial performance with a recent revenue of approximately $13.59 billion, indicating a year-over-year growth of 7.2%, which reflects the company's ability to expand its market presence.
  • The company boasts a high return on equity of 32.23%, suggesting effective management and profitability in generating returns for shareholders.
  • Analysts have a consensus rating of "Buy" for AstraZeneca, with an average target price of around $85.00, indicating positive market sentiment and potential for stock appreciation.
  • The current stock price is approximately $75.00, which is seen as a favorable entry point for investors looking to capitalize on future growth.
  • AstraZeneca's net margin of 13.01% highlights its efficiency in converting revenue into profit, which is a positive indicator for long-term sustainability and profitability.

AstraZeneca
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in AstraZeneca for these reasons:

  • The company's recent revenue fell short of analysts' expectations, which could raise concerns about its ability to meet future growth targets.
  • Despite positive growth, the competitive landscape in the biopharmaceutical industry is intense, which may impact AstraZeneca's market share and pricing power.
  • One analyst has rated the stock with a hold rating, suggesting that there may be uncertainty regarding its short-term performance.
  • Market volatility can affect AstraZeneca's stock price, and external factors such as regulatory changes or patent expirations could pose risks to its profitability.
  • Investors may be cautious due to the potential for fluctuations in earnings per share, with forecasts indicating a projected EPS of 4.51 for the current year, which may not meet investor expectations.

AZN Forecast - Frequently Asked Questions

According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for AstraZeneca is $85.00, with a high forecast of $95.00 and a low forecast of $75.00.

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There is currently 1 hold rating, 5 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AZN shares.

According to analysts, AstraZeneca's stock has a predicted upside of 16.42% based on their 12-month stock forecasts.

AstraZeneca has been rated by research analysts at BNP Paribas in the past 90 days.

Analysts like AstraZeneca more than other "medical" companies. The consensus rating for AstraZeneca is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how AZN compares to other companies.


This page (NASDAQ:AZN) was last updated on 6/10/2025 by MarketBeat.com Staff
From Our Partners